Camargo Pharmaceutical Services LLC, a United States-based drug development and commercial partner, is acquiring Paidion Research Inc, a global paediatric clinical research organisation in the United States, it was reported on Tuesday.
Camargo says that this is its second acquisition to expand services in order to offer leading integrated solutions designed to meet the requirements of emerging biopharma companies addressing unmet medical requirements in rare and complex areas.
Camargo CEO, Dan Duffy, said, 'Half of all patients affected by a rare disease are children. Paediatric research is critical to success as we work to deliver a comprehensive solution to emerging biopharma companies with specialised needs. We are proud to partner with the Paidion team, who have earned their reputation as the leader in paediatric clinical research.'
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval